Zahra A, Tahir A, Iqbal M, Shahzad M, et al. A real-world analysis of second-line treatment option, Gemcitabine plus Anlotinib and anti-PD1, in advanced pancreatic cancer: A critical insight. Pancreatology 2025 Jun 12:S1424-3903(25)00118-8. doi: 10.1016/j.pan.2025.
PMID: 40537338